Clinical Trial Update: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study of SPI-62 in ACTH-dependent Cushing's syndrome (Cushing disease) has completed. The document lists Sparrow Pharmaceuticals as sponsor but does not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease
• Cushing Syndrome

Drugs mentioned

• SPI-62

Snippet

Sponsor: Sparrow Pharmaceuticals | Conditions: Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Status: COMPLETED